Eplerenone ( DrugBank: Eplerenone )

4 diseases

75. クッシング病

臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000002925	2009/12/01	28/12/2009	Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.	Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. - A pilot study to compare efficacy of Eplerenone monotherapy with Valsartan monotherapy.	Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.	50mg of Eplerenone monotherapy once daily for 6 weeks on subclinical Cushing's syndrome 80mg of Valsartan monotherapy once daily for 6 weeks on subclinical Cushing's syndrome 50mg of Eplerenone monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma 80mg of Valsartan monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma	Hiroshima University HospitalDepartment of Endocrinology and Diabetes mellitus	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	80	Not selected	Japan

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02354352 (ClinicalTrials.gov)	March 20, 2015	27/1/2015	Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy	Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy	Drug: Eplerenone;Drug: Spironolactone	Ohio State University	University of California, Los Angeles;University of Utah;University of Colorado, Denver;University of Kansas Medical Center;Vanderbilt University Medical Center	Completed	7 Years	N/A	Male	52	Phase 3	United States
2	NCT01521546 (ClinicalTrials.gov)	February 2012	26/1/2012	Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy	Early Treatment With Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy	Drug: eplerenone;Drug: placebo	Subha Raman	Ballou Skies	Completed	7 Years	N/A	Male	42	N/A	United States

臨床試験数 : 51 / 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01971593 (ClinicalTrials.gov)	August 2013	23/10/2013	The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease	Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease	Tetralogy of Fallot;Transposition of the Great Vessels With an Arterial Switch;Single Ventricle With a Fontan Palliation	Drug: Eplerenone	Washington University School of Medicine	Pfizer	Terminated	18 Years	80 Years	All	26	Phase 4	United States

臨床試験数 : 18 / 薬物数 : 26 - (DrugBank : 14) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01971593 (ClinicalTrials.gov)	August 2013	23/10/2013	The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease	Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease	Tetralogy of Fallot;Transposition of the Great Vessels With an Arterial Switch;Single Ventricle With a Fontan Palliation	Drug: Eplerenone	Washington University School of Medicine	Pfizer	Terminated	18 Years	80 Years	All	26	Phase 4	United States